Geniposide and chlorogenic acid (GC) are effective ingredients of Gardenia jasminoides and Herba Artemisiae capillaris, respectively. Previous studies indicated that the GC treatment could alleviate experimental NASH in rats induced by high fat diet. Recently, we established a rat NASH model of high fat diet in addition to dextran sulfate sodium (DSS) treatment, which features increased gut permeability. With this NASH model, we aimed to evaluate the effects of GC treatment and the underlying mechanisms. Methods: Sixteen male SD rats were given high fat diet and DSS (1% in drinking water) for 26 weeks. The rats were randomly divided into GC treatment group
(n=8) and control
Selleck Veliparib (water treatment) group (n=8). The medicine or distilled water was administered by gavage from the 23rd week to the end of the 26th week, when portal blood, peripheral blood, liver, and intestines were collected. Liver triglyceride (TG) content, serum fasting glucose and insulin, FK506 ic50 serum alanine aminotrans-ferase (ALT), and serum LPS were determined. Liver and colon pathologies were evaluated by hematoxylin-eosin (H&E) and Oil red O staining of the cryosections. The mRNA expression of liver tumor necrosis factor-α (TNF-α) was examined by quantitative real-time PCR. Results: Liver TG content (GC/ Control =166.7±6.1 /222.7±21.0mg/dl, p =0.0361), serum ALT (GC/Control 36.4±2.8/52.1±5.7U, p =0.0226), portal serum LPS level MCE公司 (GC/Control =0.11±0.01/0.17±0.02 EU/ml, p =0.0135) and liver TNF-α mRNA expression
(GC/Control =1.62±0.39/2.48±0.38, p =0.046) were lower in the GC treatment group compared with those of the control group. GC treated animals exhibited improved liver pathologies for both steatosis (Oil red O staining) and inflammation (H&E staining). Importantly, H&E staining indicated that GC treatment suppressed colon inflammation. Conclusion: Suppressed colon inflammation and decreased serum LPS in the GC treatment group suggested that the GC therapy has a beneficial effect on gut barrier function. This may contributeto the therapeutic effect GC has on liver steatosis and inflammation. A time course study is needed to confirm a causal relationship between improved gut barrier and the improved liver health. Disclosures: The following people have nothing to disclose: Qin Feng, Susan S. Baker, Wensheng Liu, Ricardo A. Arbizu, Ghanim Aljomah, Maan Khatib, Colleen A. Nugent, Robert D. Baker, Yiyang Hu, Lixin Zhu Background and Aim: Non-alcoholic steatohepatitis (NASH) is emerging worldwide and progresses to cirrhosis with/without hepatocellular carcinoma. Any useful marker to differentiate NASH from non-alcoholic fatty liver disease is not available, and the diagnosis of NASH needs liver biopsy besides radiological findings.